Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer
Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, et al.
Clinical Breast Cancer
|
February 14, 2008
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer
Robert Paridaens, Luc Dirix, Herlinde Dumez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2010
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer
Giorgio Scagliotti, Thomas Brodowicz, Frances A Shepherd, et al.
The Lancet. Oncology
|
November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
Edward S Kim, Marcus Neubauer, Allen Cohn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 3, 2010
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer
Silvia Novello, Francisco Luis Pimentel, Jean-Yves Douillard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
Antonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2008
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S Albain, Shona M Nag, German Calderillo-Ruiz, et al.
Military Medicine
|
December 2, 2022
Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm)
Robert Paine, Robert Chasse, E Scott Halstead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
John R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer
Christian Dittrich, Lubos Petruzelka, Pavel Vodvarka, et al.
Clinical Breast Cancer
|
February 14, 2008
Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer
Robert Paridaens, Luc Dirix, Herlinde Dumez, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2010
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer
Giorgio Scagliotti, Thomas Brodowicz, Frances A Shepherd, et al.
The Lancet. Oncology
|
November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
Edward S Kim, Marcus Neubauer, Allen Cohn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 3, 2010
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer
Silvia Novello, Francisco Luis Pimentel, Jean-Yves Douillard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer
Antonio Llombart-Cussac, Miguel Martin, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2008
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S Albain, Shona M Nag, German Calderillo-Ruiz, et al.
Military Medicine
|
December 2, 2022
Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm)
Robert Paine, Robert Chasse, E Scott Halstead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2008
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2014
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
John R Mackey, Manuel Ramos-Vazquez, Oleg Lipatov, et al.
Page
of 3